Released Nov 12, 2026, before the open
10-Q filed Nov 13, 2026, 44 days after period end · 0001193125-26-458896
On October 19, 2026, Silence announced ( press release ) that it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 |
|---|---|---|---|
| Revenue | $0.00 | $159.00K | $1.50M |
| Net Income | -$12.43M | -$20.96M | -$35.54M |
| EPS Diluted |
Silence Therapeutics plc · CIK 1479615 · Engraved from SEC EDGAR
| -$0.08 |
| -$0.15 |
| -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Silence Therapeutics reported a net loss of $12.4 million, or $0.08 basic and diluted net loss per share, for the three months ended September 30, 2026, compared to a net loss of $21.0 million, or $0.15 per share, a year earlier.¶2
Research and development expenses were $9.3 million for the three months ended September 30, 2026, compared to $20.5 million a year earlier, a decrease the filing mainly attributes to completed zerlasiran Phase 3 readiness work in 2025 and reduced personnel costs.¶3
Cash and cash equivalents were $247.7 million as of September 30, 2026, including $201.3 million in gross proceeds from an upsized public offering announced on August 11, 2026.¶4
On October 19, 2026, Silence entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, with closing expected in the first quarter of 2027, subject to customary closing conditions.¶1